MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Galectin Therapeutics Depreciation & Amortization 2011-2026 | GALT
Annual Depreciation & Amortization Galectin Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 1 K | 7 K | 7 K | 10 K | 12 K | 9 K | 9 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12 K | 1 K | 7.86 K |
Quarterly Depreciation & Amortization Galectin Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 K | 1 K | 1 K | - | 5 K | 3 K | 1 K | - | 6 K | 4 K | 2 K | - | 8 K | 5 K | 2 K | - | 9 K | 6 K | 3 K | - | 5 K | 4 K | 2 K | - | 7 K | 5 K | 2 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9 K | 1 K | 3.9 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Benitec Biopharma
BNTC
|
66 K | $ 10.98 | -4.52 % | $ 452 M |  USA |
 |
Milestone Pharmaceuticals
MIST
|
114 K | $ 1.36 | -20.0 % | $ 45.5 M |  Canada |
 |
Pharming Group N.V.
PHAR
|
7.28 M | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
PainReform Ltd.
PRFX
|
7 K | $ 2.28 | -0.44 % | $ 1.03 M |  Israel |
 |
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
63 K | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | Canada |
 |
Assembly Biosciences
ASMB
|
129 K | $ 28.46 | 3.45 % | $ 319 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.37 | -4.2 % | $ 350 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Axsome Therapeutics
AXSM
|
503 K | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | Israel |
 |
AbCellera Biologics
ABCL
|
18.4 M | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioMarin Pharmaceutical
BMRN
|
79.6 M | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Calithera Biosciences
CALA
|
300 K | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
259 K | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | USA |
 |
Compugen Ltd.
CGEN
|
461 K | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Coherus BioSciences
CHRS
|
1.3 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Clovis Oncology
CLVS
|
8.5 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
233 K | $ 8.6 | -3.8 % | $ 115 M | USA |
 |
Curis
CRIS
|
203 K | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |